Citation bias favoring positive clinical trials of thrombolytics for acute ischemic stroke: a cross-sectional analysis

Table 1 Publication characteristics and citation rates for included trials of thrombolytics for stroke

Trial	Year published	Patients enrolled	Location	Journal	Intervention	Jadad score	Result	Total citations	Citations per year
NINDS [11]	1995	624	US	NEJM	IV tPA	5	Positive	6622	330
ECASS III [12]	2008	821	Europe	NEJM	IV tPA	5	Positive	2458	335
ECASS [13]	1995	620	Europe	JAMA	IV tPA	5	Neutral	2138	106
ECASS II [14]	1998	800	Europe, Australia, NZ	Lancet	IV tPA	5	Neutral	1768	102
EPITHET [15]	2008	101	Australia, NZ, Belgium, UK	Lancet Neurology	IV tPA	5	Neutral	561	72
IST-3 [16]	2012	3035	Europe, Canada, Mexico, Australia	Lancet	IV tPA	3	Neutral	380	104
ATLANTIS B [17]	1999	613	US, Canada	JAMA	IV tPA	5	Negative	820	51
ATLANTIS A [18]	2000	142	US	Stroke	IV tPA	5	Negative	276	18
PROACT II [19]	1999	180	US, Canada	JAMA	IA pro-urokinase	3	Positive	2287	142
DIAS [20]	2005	104	Europe, Australia, Singapore	Stroke	IV desmoteplase	5	Positive	749	69
DIAS-2 [21]	2009	193	Australia, Europe, US, Canada, China, Singapore	Lancet Neurology	IV desmoteplase	5	Neutral	332	49
MELT [22]	2007	114	Japan	Stroke	IA urokinase	3	Neutral	282	34
ASK [23]	1996	340	Australia	JAMA	IV streptokinase	5	Negative	328	17
MAST-E [24]	1996	310	Europe	NEJM	IV streptokinase	5	Negative	421	22
MAST-I [25]	1995	622	Europe	Lancet	IV streptokinase	3	Negative	551	27

IA intra-arterial, IV intravenous, JAMA Journal of the American Medical Association, NEJM New England Journal of Medicine, NZ New Zealand, tPA alteplase, US United States, UK United Kingdom

ISSN: 1745-6215